CLTEF News and Press, Calliditas Therapeutics AB - Class B

2024-06-02 03:00:00 ET Summary Suzhou MediLink partners with BioNTech to use its antibody-drug conjugate platform, receiving an upfront payment of $25 million and up to $1.8 billion in milestones. Asahi Kasei offers $1.1 billion to acquire Calliditas Therapeutics, aiming to expand...

2024-05-28 10:20:20 ET Summary Asahi Kasei will acquire Calliditas Therapeutics AB (publ) for $1.1 billion, representing an 83% premium to the closing price on the Stockholm exchange and a 74% premium to the Nasdaq closing price. The primary asset of interest in the acquisition is...

2024-05-23 15:11:04 ET Calliditas Therapeutics AB (publ) (CALT) Q1 2024 Earnings Conference Call May 23, 2024 8:30 AM ET Company Participants Renee Aguiar-Lucander - CEO Richard Philipson - CMO Maria Tornsen - President, North America Fredrik Johansson - CFO ...

2024-02-21 17:46:07 ET Calliditas Therapeutics AB (publ) (CALT) Q4 2023 Earnings Call Transcript February 21, 2024, 08:30 AM ET Company Participants Renee Aguiar-Lucander - CEO Richard Philipson - CMO Maria Tornsen - President, North America Fredrik Johansson...

2024-01-25 15:30:27 ET Summary Vera Therapeutics, Inc. stock price soared over 35% today as it announced positive results from the open label extension of its Phase 2b ORIGIN clinical trial for atacicept in IgA nephropathy. The company's stock is up over 160% in the past year and ...

2024-01-14 12:00:24 ET More on CRISPR, GSK, etc. Pfizer Is Part Of The 2024 Healthcare Sector Rally Cohort Impact Of Gene Therapies And Casgevy On Crispr AG And The Industry CRISPR Therapeutics AG (CRSP) 42nd Annual J.P. Morgan Healthcare Conference (Transcript) ...

2023-12-03 04:30:00 ET Summary LianBio, a Princeton-Shanghai in-licensing company, received a $465 million buyout offer from Tang Capital Management. Perpetual Medicines, a Shanghai-Boston AI startup, closed an $8 million seed financing to advance its peptide drug discovery platfo...

2023-11-27 18:40:01 ET Summary Q3 2023 sales for Calliditas Therapeutics' flagship drug Tarpeyo fell short of expectations but showed incremental growth. Despite challenges, the number of prescribers and improvements in market access for Tarpeyo indicate long-term success. 202...

2023-11-24 08:00:38 ET More on Calliditas Therapeutics Calliditas: Q2 Earnings De-Risk This Biotech Play, 2024 Expected To Be Inflection Point Calliditas stock dips as losses widen in Q3 Seeking Alpha’s Quant Rating on Calliditas Therapeutics Historica...

2023-07-20 18:36:07 ET Summary We maintain a buy rating due to promising interim data from the Phase II trial of setanaxib in patients with squamous cell carcinoma of the head and neck and potential Q2 earnings from Tarpeyo's sales. Despite promising interim data, the market has y...